Persistent Borrelia burgdorferi protein antigen in CD16⁺ monocytes is associated with monocyte-skewed immune dysregulation in post-treatment Lyme disease syndrome (PTLDS)
This study demonstrates that persistent *Borrelia burgdorferi* protein antigens within CD14⁺CD16⁺ monocytes, rather than ongoing bacterial infection, drive monocyte-skewed immune dysregulation and inflammatory transcriptional changes in patients with post-treatment Lyme disease syndrome (PTLDS).
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
For millions of people, a tick bite leads to a treatable infection, but for a significant minority, the story does not end when the antibiotics stop. These individuals, diagnosed with Lyme disease and treated according to standard medical guidelines, continue to suffer from deep fatigue, joint pain, and brain fog for months or even years. This lingering condition, known as post-treatment Lyme disease syndrome, has long puzzled doctors and scientists. The central question has been whether the bacteria that caused the illness are still hiding in the body, quietly multiplying and causing trouble, or if the symptoms are the result of the immune system getting stuck in a state of high alert long after the invader has been defeated. Resolving this mystery is critical because the answer dictates the treatment: if live bacteria remain, stronger or longer antibiotic courses might be the cure; if the bacteria are gone but the immune system is still reacting to leftover debris, then the focus must shift to calming the body's own defenses.
A new study by researchers at HealthBio Inc. and Stanford University offers a compelling answer to this question by looking directly inside the blood cells of patients who still feel sick. The team focused on a specific type of white blood cell called a monocyte, which acts as a patrol guard in the bloodstream, constantly scanning for foreign invaders. They suspected that these cells might be holding onto pieces of the Lyme bacteria, much like a security guard might keep a piece of evidence in a pocket long after the crime scene has been cleared. To test this, the researchers collected blood from ten patients who had been treated for Lyme disease but still suffered from persistent symptoms. They carefully isolated the monocytes from the blood and used a highly sensitive technique called mass spectrometry to search for the molecular fingerprints of the Lyme bacteria, specifically looking for two proteins known as FlaB and OspC.
The results were striking. In 4 of the 10 patients, the researchers found clear evidence of these bacterial proteins sitting inside the monocytes, even though the patients had been treated months or years earlier. Of these 4 patients, 3 were analyzed in depth. However, when the team looked for the genetic instructions that would indicate the bacteria were alive and actively making copies of themselves, they found nothing. The bacteria's DNA was not being read, and no new bacterial proteins were being produced. This distinction is vital: it suggests that the bacteria are not actively infecting the body in these patients. Instead, the immune cells are carrying fragments of the dead bacteria, remnants that the body has failed to fully break down or discard.
The presence of these leftover bacterial pieces appears to be driving a specific kind of immune chaos. The researchers analyzed the genetic activity of the blood cells and found that the patients carrying these bacterial fragments had a distinct pattern of gene expression. Their immune systems were in a state of constant, low-level alarm, with genes related to inflammation and cell signaling turned on high. This included a surge in signals that recruit other immune cells and activate pathways typically used to fight off active infections. When the team looked at the blood plasma, they found that levels of certain inflammatory chemicals, such as interferon-gamma, were elevated in all the patients, but the pattern was most pronounced in those carrying the bacterial fragments. The immune system seemed to be reacting to the presence of the debris as if it were a fresh threat, creating a cycle of inflammation that causes the persistent symptoms.
This finding aligns with what has been observed in other post-infectious conditions, such as long COVID, where pieces of the virus have been found lingering in similar immune cells. The study suggests that the problem in these Lyme patients is not a failure of the antibiotics to kill the bacteria, but rather a failure of the body to clear the evidence of the battle. The immune system, having been trained to fight the bacteria, continues to react to the leftover pieces, keeping the body in a state of chronic inflammation. The researchers note that this does not mean every patient with lingering symptoms has this specific issue, as some patients in the study did not show these bacterial fragments, implying that different mechanisms might be at play for different people. However, for the group where these fragments were found, the data points away from the need for more antibiotics and toward the possibility that treatments designed to reset or calm the immune system could be the key to recovery. The study provides a concrete biological explanation for why some people feel sick long after the infection is gone, shifting the focus from hunting a ghost to understanding why the body's defenses remain on high alert.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.